Hoperab-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, designed to manage gastrointestinal disorders characterized by acid reflux, dyspepsia, and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and discomfort associated with gastroparesis and functional dyspepsia. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of Domperidone and Rabeprazole in Hoperab-DSR Capsule offers comprehensive management of upper gastrointestinal symptoms by both promoting motility and reducing acid secretion. This combination is particularly beneficial in patients who require acid suppression along with prokinetic support. Hoperab-DSR Capsule should be used under medical supervision, with dosage adjustments based on clinical response and patient tolerance. Contraindications include hypersensitivity to either component, and caution is advised in patients with cardiac arrhythmias or prolonged QT interval due to Domperidone’s potential cardiac effects.